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Abstract
Objective: The aim of this study was to compare the effects in terms of resistance to fracture of the mandibular 
condyle and femoral head following different doses of zoledronic acid in an animal model. 
Study design: A total of 80 adult male Sprague-Dawley rats were included in a prospective randomized study. 
The animals were randomly divided into four groups of 20 rats each. Group 1 (control) received sterile saline 
solution, while groups 2, 3 and 4 received a accumulated dose of 0.2 mg, 0.4 mg and 0.6 mg of zoledronic acid, 
respectively. The animals were sacrificed 28 days after the last dose, and the right hemimandible and the right 
femur were removed. The fracture strength was measured (in Newtons) with a universal test machine using a 1 
kN load connected to a metal rod with one end angled at 30 degrees. The cross-head speed was 1 mm/min. Later, 
the specimens were observed under a scanning electron microscope with backscattered electron imaging (SEM-
BSE). At last, chemical analysis and elemental mapping of the mineral bone composition were generated using a 
microanalytical system based on energy-dispersive and X-ray spectrometry (EDX). 
Results: A total of 160 fracture tests were performed. The fracture resistance increased in mandible and femur 
with a higher accumulated dose of zoledronic acid. Statistically significant differences were recorded versus 
the controls with all the studies groups. The chemical analysis in mandible showed a significantly increased of 
calcium and phosphorous to compare the control with all of the study groups; however, in femur no statistically 
significant differences between the four study groups were observed. 
Conclusions: The administration of bisphosphonates increases the fracture resistance in mandible and femur.   
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Introduction
The mechanical properties of bone directly condition 
fracture risk and are the best indicators of bone strength 
(1-7). Bisphosphonates decrease bone resorption, increase 
bone mineral density and decrease the risk of fracture. 
Zoledronic acid is a nitrogen-containing, highly potent 
bisphosphonate, and is commonly used as supportive 
treatment for cancer patients. Currently, it has also been 
approved in a single dose/year regimen for the treat-
ment of postmenopausal osteoporosis. The zoledronic 
acid and other oral and intravenous bisphosphonates are 
associated with osteonecrosis of the jaw. This type of 
osteonecrosis is limited to the craniofacial region and 
its physiopathology is not known (2,8).
The specific pharmacological properties of bisphospho-
nates include selective uptake in the skeleton, prefer-
entially at sites of active bone remodeling, where they 
decrease bone resorption mainly through direct effects 
upon the osteoclasts.
The high bone turnover rate in the jaw, probably a 
consequence of its high mechanical load, may lead to 
an increased local uptake of bisphosphonate and thus 
contributing to the development of osteonecrosis in 
this location (1,3,9). Although some authors like Baus 
et al. (5) have shown that in rats given different doses 
of ibandronate, the uptake of this bisphosphonate in the 
mandible is relatively similar to that seen in other bones 
of the skeleton.
Although the modifications in bone hardness after bi-
sphosphonates administration have been systematically 
documented, the cause of such changes remains unclear 
(9). Determining the cause of lessened resistance is be-
coming particularly relevant in the light of the recent 
increase in the incidence of atypical femoral fractures 
presenting features consistent with reduced bone resist-
ance (1,7,8).
In this sense, the objective of the present study was to 
compare the effects upon fracture resistance of the man-
dibular condyle and femoral head with different doses 
of zoledronic acid in an animal model, and analyze the 
mineral composition of these bones.
Material and Methods
-Experimentation animals 
The animals used in this study were obtained from the 
Experimentation Animals Unit (Support for Research 
Unit) from University of Murcia (Spain).
A total of 80 adult male Sprague-Dawley rats with a 
mean weight of 250 g (range 210-270 g) were included in 
this prospective randomized study, following a protocol 
approved by the Bioethics Committee of the University 
of Murcia (Spain). The study was carried out between 
January and September 2010. The animals were indi-
vidually housed in plastic cages in a monitored environ-
ment (21º C and 12: 12 hours light: darkness cycle). The 
rats were acclimatized for one week before the start of 
the study, and had free access to drinking water and a 
standard laboratory rat food pellet diet. The entire study 
was carried out in abidance with the corresponding Eu-
ropean Union guidelines.
The animals were randomly divided into four groups 
of 20 rats each. Group 1 (control) received sterile saline 
solution, while groups 2, 3 and 4 received a accumu-
lated dose of 0.2 mg, 0.4 mg and 0.6 mg of zoledronic 
acid, respectively; through a single weekly intraperito-
neal dose consisted in zoledronic acid of 0.2 mg/250 g 
(Table 1). The amount of drug to be administered was 
extrapolated from the amount of drug received by pa-
tients for cancer-related bone disease (4).
The animals were sacrificed with carbon dioxide 28 
days after the last dose. Immediately after sacrifice, the 
right hemimandible and femur were removed.
Samples for biomechanical testing were wrapped in sa-
line-soaked gauze and frozen at -20ºC until testing. The 
samples were posteriorly thawed at room temperature 
and immersed in saline solution 5 minutes before test-
ing to allow temperature equilibration.
-Fracture resistance (biomechanical testing procedure)
Specimens from the mandible and femur were mounted 
in a 40 mm long copper cylinder with an internal di-
ameter of 30 mm, inserting half the length in plaster. 
The fracture strength of the hemimandibular condyle 
and the femoral head was measured (in Newtons) us-
ing a universal test machine (Autograph AGS-1KND, 
Group 1
n=20
Group 2
n=20
Group 3
n=20
Group 4
n=20
Control x
Zoledronic acid administration in weeks                                          1 2 3
Accumulated dose (mg)                                                                                                              0.20 0.40 0.60
Nº of animals sacrificed at 28 days after the last dose         20 20 20 20
Nº of fractures in right mandibular condyle                             20 20 20 20
Nº of fractures in right femoral head                                                                      20 20 20 20
Table 1. Study design (n = 80 male Sprague-Dawley rats). 
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Shimadzu, Kyoto, Japan) with a 1 kN load connected 
to a metal rod with one end angled at 30 degrees. The 
cross-head speed was 1 mm/min.
-Study of the samples with the scanning electron mi-
croscope
The samples were processed (through carbon bath) for 
their observation to the scanning electron microscope 
(SEM-BSE) (Oxford Instruments INCA 300 EDX Sys-
tem, Abingdon, Oxfordshire, Reino Unido). All obser-
vations were carried out to a distance of 19 mm, a volt-
age of 15 kv and a 15 × magnification.
-Chemical analysis of the mineral bone composition 
(microanalysis of elements)
At last, we perform an analysis of the mineral bone 
composition using a microanalytical system based on 
energy-dispersive and X-ray spectrometry (EDX) (Fig. 
1). This system allows evaluating the relative concen-
tration of all the chemical elements present in the bone, 
using a timely analysis and elemental mapping to deter-
mine the mineral distribution. The relative concentra-
tion of each element is indicated by a color scale, where 
for each element, the dark blue color indicates the abso-
lute zero and white indicates the concentration absolute 
100% of that element.
-Statistical analysis
The data were analyzed using the SPSS version 12.0 sta-
tistical package (SPSS® Inc., Chicago, IL, USA). The 
study was designed with an 80% statistical power, as-
suming security of 95%. A descriptive study was made 
of each variable. The Kolmogorov-Smirnov normality 
test and Levene variance homogeneity test were ap-
plied, and the data showing a skewed distribution were 
analyzed using a nonparametric ranking test. We used 
the Mann-Whitney U-test (for two independent sam-
ples), for quantitative variables. Statistical significance 
was accepted for p£0.05.
Fig. 1. Chemical microanálisis of the mineral bone composition based on energy-dispersive and 
X-ray spectrometry (EDX),  showing a section of bone using scanning electron microscope, and 
the spectrum of elements in the sample.
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Fig. 3. Microfracture in femur next to the central fracture zone 
in the femoral head.
Group n Strength of fracture (Nw)
Median (range)
Mandible
Control 20 40.2 (24.5-57.0)a
0.2 mg CD* of ZA**   20 58.5 (30.5-88.5)b
0.4 mg CD of ZA         20 66.5 (51.5-78.5)b
0.6 mg CD of ZA         20 71.5 (46.0-88.5)b
Femur
Control 20 102.0 (66.5-127.5)c
0.2 mg CD of ZA         20 144.0 (47.5-222.5)d
0.4 mg CD of ZA         20 144.5 (75.5-203.5)d
0.6 mg CD of ZA         20 138.2 (72.5-210.5)d
Table 2. Results of the bone fracture tests (Mann-Whitney U test).
* CD = Cumulate Doses; ** ZA = Zoledronic Acid. Groups marked 
by different superscript letters showed significant differences (the 
superscript for mandible are a and b, and for femur c and d)
Fig. 2. A) Mandibular microfracture next to the central fracture 
zone in the mandibular condyle, using scanning electron micro-
scope. B) Mandibular microfracture with greater mafgnification.
Results
A total of 160 fracture tests were performed (80 in man-
dible and 80 in femur). The fracture resistance increased 
in mandible and femur with a higher accumulated dose 
of zoledronic acid. Statistically significant differences 
were recorded versus the controls with all the studies 
groups (Table 2).
The observation of specimens under a scanning elec-
tron microscope, once produced the bone fracture in the 
mandibular condyle, showed that 5 of the 20 samples 
controls (25%) had at least one microfracture next to the 
central fracture zone in the mandibular condyle (Fig. 2); 
while in groups where zoledronic acid was administered 
was not observed any microfracture adjacent to the cen-
tral fracture zone. Similarly, in the samples where the 
bone fracture was made in the femoral head, 6 of 20 
samples controls (30%) had microfractures next to the 
central fracture zone in the femoral head (Fig. 3), while 
there were no microfractures in the study groups.
The chemical analysis in mandible showed a signifi-
cantly increased of calcium and phosphorous to com-
pare the control with all of the study groups; however, 
in femur no statistically significant differences between 
the four study groups were observed (Table 3). 
Discussion
The mechanical properties of bone directly condition 
fracture risk and are the best indicators of bone strength. 
The bisphosphonates, with different degrees of potency 
and efficacy, prevent the loss of bone mineral mass and 
density In our study, the biomechanical testing showed 
the short-term administration of zoledronic acid in rats 
to increase the resistance to fracture of both mandibu-
lar condyle and femoral head; and the chemical analysis 
showed an increase in the levels of calcium and phos-
phorus in both bones, which was higher as increasing 
the cumulative dose of the bisphosphonate.
Comparing studies investigating methods on the me-
chanical properties of bone is not easy. Mechanical 
properties are additionally influenced by a variety of 
factors, such as anatomical location, specimen size and 
shape, loading mechanism, and displacement time of 
the load (7-10).
The evaluation of these biomechanical properties of bone 
is very important for assessing changes in bone mass and 
architecture. However, according to Shahnazari et al. (9), 
standardized testing protocols are not available, and the 
bone samples used are derived from different species 
with different specimen geometries types (whole bones 
versus machined specimens, cortical versus trabecular 
specimens), and different preservation fluids involving 
different concentrations are moreover used.
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Group n Calcium (%)
Median (range)
Phosphorus (%)
Median (range)
Mandible
Control 20 12.8 (0.3-35.3)a 9.5 (1.4-30.3)a
0.2 mg CD* de ZA*     20 22.8 (1.6-33.6)b 16.1 (2.1-21.3)b
0.4 mg CD de ZA       20 24.8 (10.6-34.1)b 18.4 (11.6-20.6)b
0.6 mg CD de ZA       20 25.7 (9.5-39.4)b 16.6 (4.5-19.9)b
Femur  
Control                              20 28.2 (22.4-52.5)c 17.9 (15.2-20.5)c
0.2 mg CD of ZA             20 29.3 (1.9-42.8)c 19.6 (11.5-24.4)c
0.4 mg CD of ZA             20 28.3 (22.1-29.4)c 18.3 (12.8-25.6)c
0.6 mg CD of ZA             20 28.3 (20.6-48.5)c 20.6 (13.5-25.4)c
Table 3. Relative concentration of calcium and phosphorus based on measurement of energy-
dispersive and X-ray spectrometry by scanning electron microscope (Mann-Whitney U test).
* CD = Cumulate Doses; ** ZA = Zoledronic Acid. Groups marked by different superscript let-
ters showed significant differences (the superscript for mandible are a and b, and for femur c)
Only in animals or material from cadavers can destruc-
tive analytical techniques be used, such as the triple-
point flexion test or vertebral body resistance to com-
pression, based on universal material analyzing systems 
and specific software applications. Basically, the aim is 
to quantify structural parameters such as bone resis-
tance to fracture (maximum load or fracture load). In 
our study testing was carried out under conditions of 
controlled displacement at a cross-head speed of 1 mm/
min. The objective of this speed was to avoid any dy-
namic effect, in accordance with other authors (8-10).
In recent years there has been an important increase in 
the number of experimental models developed to un-
derstand the mechanisms by which bisphosphonates 
exert preventive effects against skeletal complications 
in malignant diseases characterized by the develop-
ment of bone metastases (11,12). Reductions in fracture 
risk in bisphosphonate-treated patients are assumed to 
be the result of improved or maintained bone biome-
chanical properties. However, there is concern that an 
exaggerated increase in bone mass not accompanied by 
improvement in bone architecture may affect the qual-
ity of bone. Increased biomechanical properties of the 
whole bone are partially offset by adverse changes in 
the bone material (7). In addition, one of the limitations 
of the biomechanical in rodent studies is the difficulty 
to extrapolate the results to human beings, due to the 
differences in bone metabolism of both species.
Bisphosphonates have specific pharmacological proper-
ties that differentiate them from all other bone resorp-
tion inhibitors, including long-term retention within the 
skeleton and persistence of their effects after the dis-
continuation of treatment (2,3,13-16). This effect would 
keep properties improved biomechanical of bone, at 
least in the short term of time after stopping use.
In our study, the administration of bisphosphonates in 
Sprague-Dawley rats, increased the fracture resistance 
in mandible and femur as well as improved the levels of 
calcium and phosphorous. However, studies are needed 
to determine if the improvement in bone biomechani-
cal properties, as well as the mineral composition of the 
bone in experimental animals, retains long-term time 
after treatment with bisphosphonates drugs stopping.
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